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Oxidative stressBiliverdin reductase-A is a pleiotropic enzyme involved not only in the reduction of biliverdin-IX-alpha into
bilirubin-IX-alpha, but also in the regulation of glucose metabolism and cell growth secondary to its serine/
threonine/tyrosine kinase activity. Together with heme oxygenase, whose metabolic role is to degrade heme
into biliverdin-IX-alpha, it forms a powerful system involved in the cell stress response during
neurodegenerative disorders. In this paper, an up-regulation of the biliverdin reductase-A protein levels
was found in the hippocampus of the subjects with Alzheimer disease and arguably its earliest form, mild
cognitive impairment. Moreover a signiﬁcant reduction in the phosphorylation of serine, threonine and
tyrosine residues of biliverdin reductase-A was found, and this was paralleled by a marked reduction in its
reductase activity. Interestingly, the levels of both total and phosphorylated biliverdin reductase-A were
unchanged as well as its enzymatic activity in the cerebella. These results demonstrated a dichotomy between
biliverdin reductase-A protein levels and activity in the hippocampus of subjects affected by Alzheimer
disease and mild cognitive impairment, and this effect likely is attributable to a reduction in the phosphor-
ylation of serine, threonine and tyrosine residues of biliverdin reductase-A. Consequently, not just the
increased levels of biliverdin reductase-A, but also its changed activity and phosphorylation state, should
be taken into account when considering potential biomarkers for Alzheimer disease and mild cognitive
impairment.verdin reductase; HO, heme
re, phospho-serine/threonine;
+1 859 259 5876.
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The role of oxidative and nitrosative stress in the pathogenesis of
neurodegenerative disorders is no longermatter of question [1]. In the
case of prolonged oxidative stress and neuroinﬂammation, which
characterize neurodegenerative disorders, brain tissue is under free
radical attack, and the brain reacts to this pro-oxidant condition by
up-regulating some genes involved in the cell stress response [2,3].
Among these, a main role is played by the heme oxygenase/biliverdin
reductase (HO/BVR) system, whose up-regulation is one of the earlier
events in the adaptive response to stress [4]. Heme oxygenase exists
in two main isoforms, HO-1 and HO-2. Heme oxygenase-1 (HO-1),
also known as heat shock protein (Hsp)-32, is induced by various
stimuli, including oxidative and nitrosative stress, ischemia, heatshock, bacterial lipopolysaccharide (LPS), hemin, and the neuroprotec-
tive agent leteprinim potassium (Neotroﬁn) [5–7]. Heme oxygenase-2,
the constitutive isoform, is responsive to developmental factors and
adrenal glucocorticoids [5,7]. Although HO-1 and HO-2 catalyze the
same reaction, namely the transformation of iron-protoporphyrin-
IX-alpha (heme) into ferrous iron (FeII), carbon monoxide (CO), and
biliverdin-IX-alpha (thereafter BV) [5,7], they play different roles in
protecting tissues against injuries [8,9]. The most convincing
hypothesis suggests that controlled HO-1 induction plays a pivotal
role in the earlier stages of cellular responses to tissue damage,
whereas HO-2 is constitutively expressed and is primarily involved in
maintaining cell heme homeostasis and in sensing the intracellular
levels of gaseous compounds including oxygen, nitric oxide (NO),
and CO [5,7,9]. Similarly, two isoforms of BVR were described and
named BVR-A and BVR-B [10–12]. Both these enzymes generate
bilirubin (BR), but only BVR-A reduces BV into the powerful
antioxidant molecule BR-IX-alpha (thereafter BR), whereas BVR-B
prefers the other BV isoforms, such as BV-β, BV-γ and BV-δ [10–12].
In the central nervous system (CNS), HO-2 is expressed in neuronal
populations in almost all brain areas [5], whereas the inducible
isoform is present at low levels in sparse groups of neurons, including
Table 1
Demographic information of AD andMCI subjects and age-matched controls. The values
reported are the average of 6 samples.
Age (years) Sex Brain weight (g) PMI (hours) Braak stage
Control (AD) 81 (72–87) 5M,1F 1219 (1020–1410) 2.00–3.75 I–III
AD 85 (80–92) 2M,4F 1104 (835–1260) 2.00–5.75 V–VI
Control (MCI) 82 (74–93) 4F,2M 1204 (1080–1315) 1.75–4.00 I–II
MCI 89 (82–99) 4F,2M 1102 (930–1200) 2.00–5.00 III–V
AD, Alzheimer disease; MCI, mild cognitive impairment; PMI, post-mortem interval.
Table 2
Summary of the causes of death, concomitant neuropathologies and known co-
morbidities in AD and MCI subjects and age-matched controls.
Subjects Cause of death Other neuropathologies Co-morbidities
Amyloid
angiopathy
PD Brain
tumor
Head
injury
Control AD 1 No No No No MI, CABG
Control AD 2 MI No
Control AD 3 Embolism No
Control AD 4 Mild
Control AD 5 CHF No No No Yes CHF
Control AD 6 No
AD 1 No No No No Hypertension
AD 2 No No No No
AD 3 Mild No No No Hypertension
AD 4 Severe No No No MI, peptic ulcer
AD 5 Moderate No No No
AD 6 Moderate No No No Cancer
Control MCI 1 CD No
Control MCI 2 No No No No Arrhythmias
Control MCI 3 SRD No
Control MCI 4 Bladder cancer No
Control MCI 5 Pancreatic
cancer
No No No No Anxiety
Control MCI 6 Cardiac arrest No No No No CHF
MCI 1 Heart disease Mild Yes CHF
MCI 2 CHF No
MCI 3 MI-CAD Mild
MCI 4 Moderate Yes Yes Hypertension
MCI 5 CHF No
MCI 6 CHF Moderate No No No MI
CABG, coronary artery bypass graft; CAD, coronary artery disease; CD, unspeciﬁed
cardiac disease; CHF, congestive heart failure; MI, myocardial infarction; PD, Parkinson
disease; SRD, severe respiratory disease; TIA, transient ischemic attack.
481E. Barone et al. / Biochimica et Biophysica Acta 1812 (2011) 480–487the ventromedial and paraventricular nuclei of the hypothalamus
[5,7]. Heme oxygenase-1 is also found in cells of glial lineage, where
its expression can be induced by oxidative stress [13]. Biliverdin
reductase-A is co-expressedwith HO-1 and/or HO-2 in cells of the rat
brain that express these enzymes under normal conditions. It is also
found in regions and cell types that can express heat shock-inducible
HO-1 [14].
It is noteworthy to mention that BVR-A not only transforms BV
into BR (by reducing the former's C10 [γ bridge]), but it is also a
serine/threonine/tyrosine kinase involved in various cellular func-
tions [10,11]. Interestingly, through the autophosphorylation of
speciﬁc serine residues BVR-A controls its own reductase activity
[15]. In addition, phosphorylated BVR-A interacts with members of
the mitogen activated protein kinase family, in particular the
extracellular signal-regulated kinases 1/2 (ERK1/2), and regulates
the expression of oxidative-stress-responsive genes such as HO-1 or
inducible nitric oxide synthase (iNOS) [10,16–18].
With regard to neurodegenerative disorders, the activation of the
HO/BVR-A system was demonstrated in the inferior parietal lobule,
plasma and lymphocytes of Alzheimer disease (AD) patients [19,20].
In addition, Kimpara et al. have shown that AD patients have an
increased concentration of BR in the cerebrospinal ﬂuid with respect
to control [21]. Recently Mueller et al. showed that also BVR-B is up-
regulated in plasma samples of AD patients [20]. Although these lines
of evidence corroborate the activation of the HO/BVR-A axis in AD, its
pathophysiological and clinical signiﬁcance is under debate. In fact,
although they are well recognized for cytoprotective activity, HO/
BVR-A by-products may become toxic for neurons if produced in
excess during the condition of prolonged neuroinﬂammation [22].
The aim of the current study was to investigate the levels, activity
and regulation of BVR-A in both hippocampal and cerebellum samples
of subjects affected by AD or arguably its earliest form, mild cognitive
impairment (MCI), the latter being the transitional phase between
normal aging and early AD [23]. Mild cognitive impairment shares with
ADboth pathological features, such asAβ accumulation in theneocortex
and numerous neuroﬁbrillary tangles (NFTs) in the medial temporal
lobe [23,24], which generate pro-oxidant status, and clinical aspects of
bothdisorders includingmemory loss. AmnesticMCI is characterized by
memory loss but no dementia and normal activities of daily living; AD is
characterized by both memory loss and dementia. For this reason, MCI
and AD are often compared in terms of brain damage and cellular stress
response in order to study progression of AD.
2. Materials and methods
2.1. Chemicals
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO,
USA) unless otherwise stated. Nitrocellulose membranes and elec-
trophoresis transfer system Trans-blot semi-dry Transfer Cell were
obtained from Bio-Rad (Hercules, CA, USA). Anti-mouse and anti-
rabbit IgG horseradish peroxidase conjugate secondary antibody and
ECL plus Western blot detection reagents were obtained from GE
Healthcare Bio-Sciences corp. (Piscataway, NJ, USA).
2.2. Subjects
Frozen hippocampal and cerebellar samples (n=6 each) from
well-characterized subjects with AD and MCI and respective age-
matched controls (Table 1) were obtained from the University of
Kentucky Rapid Autopsy Program of the Alzheimer's Disease Clinical
Center (UK ADC) with a post-mortem interval within the range 1.75–
5.75 h for AD and MCI patients and relative control subjects. All the
subjects were longitudinally followed and underwent annual neuro-
psychological testing, and neurological and physical examinations.
Control subjects were without history of dementia or other neurolog-ical disorders and with intact activities of daily living (ADLs), and they
underwent annualmental status testing and semi-annual physical and
neurological exams as part of the UK ADC normal volunteer
longitudinal aging study (Table 2). The control subjects showed no
signiﬁcant histopathological alterations and the Braak score was
within the range 1–2 for theMCI age-matched controls, and1–3 for the
AD age-matched controls. Patients suffering fromMCI met the criteria
described by Petersen [23], which include: a memory complaint
supported by an informant, objective memory test impairment (age-
and education-adjusted), general normal global intellectual function,
intact ADLs, Clinical Dementia Rating score of 0.0 to 0.5, no dementia,
and a clinical evaluation that revealed no other cause for memory
decline. AD patients diagnosis was made according to criteria
developed by the National Institute of Neurological and Communica-
tive Disorders and Stroke (NINCDS) and the Alzheimer's disease and
Related Disorders Association (ADRDA) [25]. All AD patients displayed
progressive intellectual decline. The Braak scores were within the
range 3–5 and 5–6 for MCI and AD patients, respectively.
2.3. Sample preparation
Brain tissues samples (hippocampus and cerebellum) from
control, MCI and AD subjects were sonicated in Media 1 lysis buffer
(pH 7.4) containing 320 mM Sucrose, 1% of 990 mM Tris–HCl
(pH=8.8), 0.098 mM MgCl2, 0.076 mM EDTA, proteinase inhibitors
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and PMSF (40 μg/mL) and phosphatase inhibitor cocktail (Sigma-
Aldrich). Since the phosphorylation of speciﬁc Ser/Thr/Tyr residues by
BVR-A itself or other kinases (e.g. the insulin receptor kinase) is
involved in both the reductase and metabolic activities of biliverdin
reductase [10,15], kinase inhibitors could interfere with such
activities. For this reason, kinase inhibitors were not included in
Media 1 lysis buffer. Homogenates were centrifuged at 14,000g for
10 min to remove debris. Protein concentration in the supernatant
was determined by the Pierce BCAmethod (Pierce, Rockford, IL, USA).
2.4. Western blot analysis
For Western blot analyses, 50 μg of protein were denaturated in
sample buffer for 5 min at 100 °C, and proteins separated on 12%
precast Criterion gels (Bio-Rad) by electrophoresis at 100 mA for 2 h in
MOPS buffer (Bio-Rad) into Bio-Rad apparatus. The proteins from the
gels were then transferred to nitrocellulose membrane using the
Transblot-Blot SD Semi-Dry Transfer Cell at 20 mA for 2 h. Subse-
quently, the membranes were blocked at 4 °C for 1 h with fresh
blocking buffermade of 3% bovine serumalbumin (BSA) in phosphate-
buffered saline (PBS) containing 0.01% (w/v) sodium azide and 0.2%
(v/v) Tween 20 (PBST). The membranes were incubated at room
temperature in PBST for 2 h with the following primary antibodies, as
separate experiments: polyclonal anti-rabbit BVR-A (Sigma-Aldrich,
dilution 1:1000); polyclonal anti-rabbit phosphoserine and anti-
phosphothreonine (Zymed, Invitrogen, Camarillo, CA, USA, dilution
1:250); polyclonal anti-rabbit phosphotyrosine, (Zymed, Invitrogen,
Camarillo, CA, USA, dilution 1:1000); polyclonal anti-rabbit phos-
phoERK1/2 (phospho-Thr202/Tyr204; Stressgen, Ann Arbor, MI, USA,
dilution 1:1000) and polyclonal anti-rabbit β-actin (Sigma-Aldrich,
dilution 1:2000). The membranes were then washed three times for
5 min with PBST followed by incubation with anti-mouse alkaline
phosphatase or horseradish peroxidase conjugate secondary antibody
(1:3000) in PBST for 2 h at room temperature. Membranes were then
washed three times in PBST for 5 min and developed using or 5-
bromo-4-chloro-3- indolyl-phosphate/nitroblue tetrazolium (BCIP/
NBT) color developing reagent for alkaline phosphatase secondary
antibody or ECL plus WB detection reagents for horseradish peroxi-
dase conjugate secondary antibody. Blots were dried, scanned in TIF
format using Adobe Photoshop on a Canoscan 8800F (Canon) or
STORM UV transilluminator (λex=470 nm, λem=618 nm, Molecu-
lar Dynamics, Sunnyvale, CA, USA) for chemiluminescence. The images
were quantiﬁed with Image Quant TL 1D version 7.0 software (GE
Healthcare). The optical density of bands was calculated as volume
(optical density×area) adjusted for the background.
2.5. Immunoprecipitation
The immunoprecipitation procedure was performed as previously
described [26] with modiﬁcations. Brieﬂy, 150 μg of protein extracts
were dissolved in 500 μl of RIPA buffer (10 mM Tris, pH 7.6; 140 mM
NaCl; 0.5% NP40 including protease inhibitors) and then incubated
with 1 μg of anti-BVR-A antibody at 4 °C overnight. Immunocom-
plexes were collected by using protein A/G suspension for 2 h at 4 °C
and washed ﬁve times with immunoprecipitation buffer. Immuno-
precipitated biliverdin reductase was recovered by resuspending the
pellets in reducing SDS buffers and subjected to electrophoresis on
12% gels followed by Western blot analysis. Total BVR-A was used as
loading control according to Refs. [16,27].
2.6. Pro-Q diamond gel staining
For detection of BVR-A speciﬁc phosphorylation, BVR-A was
immunoprecipitated and subjected to electrophoresis as described
above. Then, the gel was stained using a Pro-Q Diamond phospho-protein gel stain kit (Molecular Probes) according to the manufac-
turer's protocol. Brieﬂy, 1-D gels were ﬁxed with 50% methanol and
10% acetic acid (100 mL per gel) for 30 min two times. Gels were then
washed three times with ultrapure water (100 mL per gel) for 30 min.
Gels were incubated in Pro-Q Diamond phosphoprotein stain solution
(100 mL per gel) for 90 min, and destained by washing three times in
50 mM sodium acetate, pH 4.0, 20% ACN (100 mL per gel) for 30 min.
Gels were then washed again three times with ultrapure water
(100 mL per gel) for 30 min each washing. Pro-Q Diamond images
were acquired using a Typhoon transilluminator with excitation/
emission wavelength of 555/580 nm. SYPRO ruby-stained gel images
were obtained using a STORM phosphoimager. All the images were
saved in TIFF format. After the ﬂuorescence scanning was completed
for each gels, the gels were incubated in ﬁxing solution (7% acetic acid,
10%methanol) for 20 min and stained overnight at room temperature
with 50 ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain
was then removed and gels stored in deionized water.
2.7. BVR-A phosphoserine/threonine and phosphotyrosine detection
For the detection of BVR-A speciﬁc phosphorylation on serine/
threonine or tyrosine residues, BVR-A immunoprecipitates were
recovered by resuspending the pellets in loading buffer, and protein
was detected byWestern blotting as previously described [16] using a
mix of anti-phosphoserine and anti-phosphothreonine primary
antibodies as described in Section 2.4. Membranes were then stripped
and re-probed by using and anti-BVR-A antibody as in Section 2.4.
Total BVR-A was used as loading control according to Ref. [27].
2.8. Biliverdin reductase activity assay
To test BVR activity in hippocampus and cerebellum samples from
AD and MCI patients the BVR assay kit (Sigma-Aldrich) was used,
following the standard protocol with minor changes. Brieﬂy, 150 μg of
protein samples were prepared for the assay and loaded in the 96 well
plate. Furthermore, BVR positive control solution (2.5, 5, 10, 15 20 μl)
was included in the assay for generation of a standard curve. Then, 50 μl
of assay buffer and 150 μl of working solution (containing NAPDH,
substrate solution and assay buffer)were added to standard and sample
on the plate. This latter was placed on the UV-VIS plate reader at 37 °C
and read every minute for 10 min. The reading after 5 min, that
presented a linear reaction rate, was chosen for BVR activity calculation.
2.9. Statistical analysis
All statistical analysis was performed using a two-tailed Student's
t-test. Pb0.05 was considered signiﬁcantly different from control.
3. Results
3.1. BVR-A protein levels in AD and MCI
Biliverdin reductase-A protein levels in hippocampus and cere-
bellum from AD and MCI subjects and age-matched controls were
measured by WB analysis. The BVR-A band intensity from control
samples normalized to β-actin was considered as 100% and the AD
andMCI values were expressed as percentage of controls. As shown in
Fig. 1, BVR-A levels were signiﬁcantly increased in hippocampal
samples from AD (Fig. 1, Panel A) and MCI (Fig. 1, Panel B) subjects.
Conversely, no signiﬁcant differences in BVR-A protein levels were
found in the cerebellum of AD and MCI subjects (Fig. 1, Panels C–D).
3.2. BVR-A phosphotyrosine and phosphoserine/threonine detection
We initially approached the study of BVR-A phosphorylation using
Pro-Q Diamond ﬂuorescent staining. ProQ Diamond is capable of
Fig. 1. Biliverdin reductase-A (BVR-A) protein levels in hippocampus and cerebellum of Alzheimer diseases (AD) and mild cognitive impairment (MCI) subjects. Brain samples of
hippocampus (panels A and B) and cerebellum (panels C and D) of subjects with AD or MCI were assayed for BVR-A by Western blot as described under Section 2.4. Densitometric
values shown in the histograms are given as percentage of Control, set as 100%, and are the product of the band value of the levels of BVR-A normalized per β-actin as loading control.
In panels A-D representative gels are shown. Data are expressed as mean±SD of six individual samples per group. *Pb0.05 and **Pb0.01 versus Control (Student's t-test).
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phosphotyrosine-containing proteins directly in sodium dodecyl
sulfate (SDS)-polyacrylamide gels. Fluorescence signal intensity of
the band correlates with the number of phosphorylated residues on
the protein. As shown in Fig. 2 the total phosphorylation signal of
BVR-A is signiﬁcantly (Pb0.05) decreased by about 55% in AD
compared to control hippocampus. However, to evaluate the extent
of phosphorylation for Ser, Thr or Tyr residues of BVR-A, speciﬁc
antibodies for pTyr, pSer, and pThr were used. pTyr-BVR-A was
signiﬁcantly decreased by 40% and 20% in AD (Fig. 3, Panel A) andMCI
(Fig. 3, Panel B) hippocampal samples, respectively, whereas noFig. 2. Biliverdin reductase-A total phosphorylation levels in hippocampus of Alzheimer
disease (AD) subjects. Representative 1D gel image of immunoprecipitated BVR-A
stained for total phosphorylation (Pro-Q Diamond) and for protein levels level (Sypro
Ruby) in control and AD hippocampus.signiﬁcant change in cerebellar tissue was found. Similarly, pSer/
pThr-BVR-A was decreased in AD (Fig. 4, Panel A) and MCI (Fig. 4,
Panel B) hippocampus (28% and 40%, respectively) and did not change
in cerebellar samples (Fig. 4, Panels C–D).
3.3. BVR activity assay
Since BVR autophosphorylation on serine residues affects its
enzymatic activity [15], the reductase activity was measured. As
shown in Fig. 5, BVR activitywas signiﬁcantly decreased in hippocampal
samples fromAD (Fig. 5, Panel A) andMCI (Fig. 5, Panel B) subjects (27%
and 40% reduction compared to their own controls, respectively). No
differences in BVR activity in the cerebellum were found (Fig. 5).
3.4. BVR-A and ERK 1/2 interaction
As BVR-A is functionally coupled to ERK1/2 and through this
pathway contributes to the regulation of oxidative stress-responsive
genes, the interactionbetween these two systemwas investigated in the
hippocampus of AD and MCI subjects. As shown in Fig. 6, phosphory-
lated ERK 2 co-immunoprecipitates with BVR-A, and its protein levels
are signiﬁcantly reduced in both AD and MCI samples. This result lends
support to the evidence that ERK-2 is linked to BVR-A and this is in good
agreement with previous data by Maines and co-workers [16].
4. Discussion
In this paper we report on the ﬁrst evidence about the regulation of
BVR-A protein levels and activity in the brain of AD and MCI subjects.
Fig. 3. Biliverdin reductase-A (BVR-A) phosphorylation on Tyrosine (Tyr) residues in hippocampus and cerebellum of Alzheimer diseases (AD) andmild cognitive impairment (MCI)
subjects. Brain samples of hippocampus (panels A and B) and cerebellum (panels C and D) of subjects with AD orMCI were immunoprecipitated by using an anti-BVR-A antibody and
assayed for phospho-Tyr (pTyr) byWestern blot as described under Sections 2.4, 2.5 and 2.7. Densitometric values shown in the histograms are given as percentage of Control, set as
100%, and are the product of the band value of the levels of pTyr-BVR-A normalized per total BVR-A as loading control. In panels A–D representative gels are shown. Data are
expressed as mean±SD of six individual samples per group. *Pb0.05 and **Pb0.01 versus Control (Student's t-test).
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ultimate scope of this paper to dissect the contribution of the HO/BVR-
A axis in the adaptive stress response in AD and MCI brains. Indeed,
the fetal isoform BVR-B [28] was recently proposed as a serum
biomarker in AD individuals [20], but the presence and pathophys-
iological role of this isoform in brain tissue needs further elucidation.
We chose to investigate the two selected brain areas for this study
because of their differential selectivity against free radical-induced
injury and pathology. Indeed, hippocampus is broadly recognized as a
main target of neurodegenerative damage during AD progression,
presenting increased levels of oxidative stress, neuronal loss and
marked atrophy in respect to whole brain [29–31]. Conversely
cerebellum is largely devoid of pathology and oxidative stress [32],
consistent with lack of AD pathology on BVR-A levels, activity and
phosphorylation state.
The ﬁrst novel ﬁnding provided by this study is the relationship
between BVR-A protein levels and activity. Total BVR-A protein levels
were increased in the hippocampus of both AD and MCI subjects, but
its activity was reduced. This result opens new avenues in the ﬁeld of
the cell stress response in AD. In fact, previous works led to the
hypothesis that an up-regulation of the HO/BVR-A axis could be
considered as a potential biomarker of AD. In this light, several groups,
including ours, demonstrated increased protein levels and activity of
HO-1/ BVR in brain, serum and lymphocytes of AD patients [4,19,20].
Furthermore, Kimpara et al. [21] demonstrated an increased concen-
tration of BR in the cerebrospinal ﬂuid of AD patients. The results
shown in our study provide a second level of comprehension for thisphenomenon and underline the importance of phosphorylation on
BVR-A activity. Maines and her group identiﬁed Gly148–Ser–Leu–
Arg–Phe–Thr–Ala–Ser–Pro as an important motif in the serine/
threonine kinase domain and demonstrated that the phosphorylation
of Ser149 is essential for BVR activity [27]. The signiﬁcant reduction of
both pSer/Thr-BVR-A (Fig. 4) and BVR activity in AD (Fig. 5) agrees
with this paradigm and conﬁrmed the importance of BVR kinase
activity even in the modulation of cell stress response. Keeping this in
mind, it is no longer correct to measure total BVR-A protein level as an
index to evaluate the involvement of this enzyme in the cell stress
response since post-translational modiﬁcations, such as the phos-
phorylation of critical Ser/Thr/Tyr residues, play a main role in the
regulation of the neuroprotective and/or metabolic activities of this
enzyme [22,33,34]. Actually, a strong increase in total BVR-A protein
levels could blunt the reduction in the Ser/Thr/Tyr phosphorylation
and the consequent decrease in the reductase activity. However, this
seems not to be the case in AD hippocampus since, despite a marked
increase in total BVR-A protein levels and a signiﬁcant reduction in
both pSer/Thr e pTyr-BVR-A, the production of BR in this tissue
remains decreased. In order to complete this intricate puzzle, the role
of BVR-B has to be also carefully considered. Whether or not in future
studies the presence of BVR-B is conﬁrmed in AD brain, the differential
contribution of both BVR isoforms to the cell stress response should be
further explored. Indeed, it is not possible to single out the differential
contribution of BVR-A and BVR-B to the generation of BR and the
improvement of the cell adaptive response. Although it is possible to
speciﬁcally measure BVR-A activity by using the alpha isomer of BV, it
Fig. 4. Biliverdin reductase-A (BVR-A) phosphorylation on Serine/Threonine (Ser/Thr) residues in hippocampus and cerebellum of Alzheimer diseases (AD) and mild cognitive
impairment (MCI) subjects. Brain samples of hippocampus (panels A and B) and cerebellum (panels C and D) of subjects with AD or MCI were immunoprecipitated by using an anti-
BVR-A antibody and assayed for phospho-Ser/Thr (pSer/Thr) by Western blot as described under Sections 2.4, 2.5 and 2.7). Densitometric values shown in the histograms are given
as percentage of Control, set as 100%, and are the product of the band value of the levels of pSer/Thr-BVR-A normalized per total BVR-A as loading control. In panels A-D
representative gels are shown. Data are expressed as mean±SD of six individual samples per group. **Pb0.01 versus Control (Student's t-test).
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BV-δ and BV-γ are also substrates for BVR-A [12].
As mentioned above, through its Ser/Thr/Tyr kinase activities BVR-
A is implicated in cell growth and apoptosis as well as glucose
metabolism. Speciﬁc Tyr residues of BVR-A, particularly Tyr198,
Tyr228 and Tyr291, are substrates for insulin receptor kinase (IRK)-1,
and phosphorylated BVR serves as a Ser/Thr kinase for insulin
receptor substrate (IRS)-1, inhibiting the latter's phosphorylation by
the insulin receptor. These processes represent a physiologic
mechanism for increasing glucose uptake [10,15]. The reduced
phosphorylation of Ser/Thr/Tyr residues in BVR-A in AD and MCI
hippocampus shown in this study (Figs. 3 and 4) could also contribute
to a further explanation to the impaired glucose metabolism seen in
both disorders. A limitation of this study is the impossibility to
identify the single Ser/Thr/Tyr residues in BVR-A which are not
phosphorylated in the AD hippocampus. However, all the results
related to BVR-A phosphorylation and BR formation are in good
agreement with previous literature data, and therefore, it is plausible
to hypothesize that these functional changes reﬂected the molecular
modiﬁcations on speciﬁc Ser/Thr/Tyr residues.
Biliverdin reductase-A is also a crucial component of MEK1-ERK-
Elk1 signaling. Biliverdin reductase-A functions as a scaffold protein
for the activation of ERK by MEK1/2 and of Elk1 by ERK. The ﬁrst step
of this process is the formation of a ternary complex constituted by
BVR-A/MEK/ERK, which places ERK in a position that permits itsactivation by MEK. In addition, the formation of this complex allows
BVR-A to be phosphorylated by ERK. Once activated, the complex
BVR-A-ERK is separated from MEK and translocates into the nucleus
where it binds and activates Elk1, a transcription factor for the
expression of oxidative-stress-responsive genes such as HO-1 or
inducible nitric oxide synthase (iNOS) [10,16–18]. The reduced
phosphorylation of BVR-A coupled with the decreased interaction
with ERK-2 found in AD hippocampus (Fig. 6) lends support to the
hypothesis that BVR could be responsible, at least in part, for the
ERK1/2 dysregulation detected in this brain area in AD subjects [35].
That only ERK-2 co-immunoprecipitated with BVR-A in AD hippo-
campus was quite surprising. A detailed dissection of the relative
contribution of ERK-1 and ERK-2 to BVR-induced redox modiﬁcations
in AD brain requires further analysis and is out of the scope of this
paper. However, our result is corroborated by morphological ﬁndings
which demonstrated that ERK-2 is the main isoform coupled to both
senile plaques and neuroﬁbrillary tangles and that its levels are
markedly reduced in AD hippocampus and cortex [35,36].
In order to complete the analysis of thepotential role of BVR-A in AD,
it is necessary to comment on BVR-A as nuclear transporter for heme.
Biliverdin reductase-A binds heme, and translocates it from cytosol to
the nucleus, where several antioxidant genes including HO-1 are up-
regulated [17]. The result shown in Fig. 1, namely the overexpression of
BVR-A inADhippocampal samples, agreeswith previousdata showinga
signiﬁcant HO-1 induction in several brain areas and illuminates a
Fig. 5. Biliverdin reductase activity in hippocampus and cerebellum of Alzheimer
diseases (AD) and mild cognitive impairment (MCI) subjects. Brain samples of
hippocampus (panels A and B) and cerebellum (panels C and D) of subjects with AD
or MCI were assayed for BVR activity as described under Section 2.8). Values are given
as nmol of bilirubin (BR) formed per mg of protein. Data are expressed as mean±SD of
six individual samples per group. **Pb0.01 versus Control (Student's t-test). Fig. 6. Extracellular signal-regulated kinases 1/2 (ERK 1/2) phosphorylation in
hippocampus of Alzheimer diseases (AD) and mild cognitive impairment (MCI)
subjects. Brain samples of hippocampus (panels A and B) of subjects with AD or MCI
were immunoprecipitated with anti-BVR-A antibody and assayed for phospho-ERK1/2
byWestern blot as described under Sections 2.4 and 2.5. Densitometric values shown in
the histograms are given as percentage of Control, set as 100%, and are the product of
the band value of the levels of pERK 2 normalized per total BVR-A as loading control. In
panels A–B representative gels are shown. Data are expressed as mean±SD of six
individual samples per group. *Pb0.05 and **Pb0.01 versus Control (Student's t-test).
486 E. Barone et al. / Biochimica et Biophysica Acta 1812 (2011) 480–487complete spectrum of interactions between HO-1 and BVR-A, whose
ﬁnal results are due to the sum of effects related to the total versus
phosphorylated fraction of BVR-A.
Interestingly, increased BVR-A levels and reduced phosphorylation
on Ser/Thr/Tyr residues occurred also in the hippocampus of MCI
subjects, thus implying that any modiﬁcation in terms of cell stress
response is an early event in the pathogenesis and progression of AD.
Another consequence of this study is the differential pattern of
protein levels and activity of BVR in hippocampus and cerebellum.
One of the possible explanations for the lack of oxidative damage in
cerebellum characteristic of AD subjects [32] is the abundance of BVR-
A and BR in this brain area. Although the results in this paper
demonstrated that there is no evidence for an increased protein levels
and activity of BVR-A in the cerebellum of AD or MCI subjects with
respect to controls, our data are not in conﬂict with the previous
hypothesis, since no difference between control and AD or MCI
subjects was found. In fact, phosphorylation of BVR-A is not impaired
in the cerebellum of AD or MCI subjects with respect to controls, and
consequently, the levels of bilirubin-IX-alpha formed are still high,
and this antioxidant may contribute to the lack of oxidative stress in
cerebellum in AD and MCI.
However, it is important to recall that the HO-1/BVR system is not
the only one involved in cellular stress response. Two other members
of the heat shock protein family, such as Hsp60 and Hsp70, were
shown to be involved in the adaptive stress response in AD. However,
data from the literature failed to show any signiﬁcant up-regulation
of both Hsp60 and Hsp70 as well as HO-1 in the cerebellum of AD
patients [37–39].
A potential caveat to the present studies is that some of the AD and
MCI cases had evidence of mild to moderate amyloid angiopathy,
which, being associated with a potential bleeding-prone condition,conceivably could activate the HO-1/BVR system. That the results
reported were observed in hippocampus of all AD and MCI subjects
regardless of the presence or absence of amyloid angiopathy suggests
that this condition did not materially contribute to the results
observed. Nevertheless, further research will be necessary to
completely rule out a contribution of this pathology to the present
results.
In conclusion, this paper represents the ﬁrst report of phosphor-
ylation differences along with the level and activity of BVR in brain of
subjects with AD or MCI. The implication of these results for insulin
signaling and AD is profound, and research on these subjects is
ongoing in our laboratory.
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